Stay updated on Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC Clinical Trial
Sign up to get notified when there's something new on the Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC Clinical Trial page.

Latest updates to the Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC Clinical Trial page
- CheckyesterdayChange DetectedThe page’s displayed revision/version number was updated from v3.5.2 to v3.5.3, indicating a maintenance or release update to the hosting platform rather than a change to the study record content.SummaryDifference0.1%

- Check8 days agoChange DetectedThe site revision changed from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check37 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check44 days agoChange DetectedRevision label updated to v3.4.3, replacing the previous v3.4.2 revision.SummaryDifference0.1%

- Check58 days agoChange DetectedStatus updated to Terminated with <75% participation and related dates; an Informed Consent Form PDF is now listed under Study Documents (M.D. Anderson Cancer Center).SummaryDifference1%

- Check73 days agoChange DetectedAdministrative site updates were made: Revision: v3.4.2 was added and an older notice (Revision: v3.4.1) was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

Stay in the know with updates to Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC Clinical Trial page.